Abstract: TGF-beta 1 binding compositions and reagents related thereto are provided. Methods of using such compositions for therapeutic purpose are also provided.

Abstract: TGF-beta 1 binding compositions and reagents related thereto are provided. Methods of using such compositions for therapeutic purpose are also provided.

Abstract: The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind to the p19 subunit of IL-23. These antibodies, or antigen-binding portions thereof, are high affinity, neutralizing antibodies useful for the treatment of autoimmune disease.

Abstract: Anti-IL-6 antibody nucleic acids, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Abstract: The present invention provides optimized heteromeric variable region binding fragments and antibodies comprising optimized heteromeric variable region binding fragments. Preferably, the optimized heteromeric variable region binding fragments exhibit optimized activity compared to donor heteromeric variable regions and have unvaried human frameworks. The present invention also provides methods of making the optimized heteromeric variable region binding fragments.

Abstract: Provided are humanized monoclonal antibodies, and antigen-binding portions thereof, which bind acylated and unacylated human ghrelin. Such antibodies are useful for neutralizing ghrelin activity and treating disorders in which ghrelin activity is detrimental, including obesity and related disorders, and various cancers.

Abstract: An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Abstract: Humanized and chimeric antibodies are provided that specifically bind human sclerostin and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful for increasing bone mass, bone mineral density and bone strength and for the treatment of various disorders, e.g., osteoporosis, in human subject.

Abstract: Humanized antibodies, or antigen-binding portions thereof, that preferentially bind acylated ghrelin with respect to unacylated ghrelin, are disclosed. These molecules have high affinity and a slow off rate for acylated ghrelin, and neutralize acylated ghrelin activity. These antibodies, or antigen-binding portions thereof, are useful for neutralizing acylated ghrelin activity, e.g., in a subject suffering from a disorder in which ghrelin activity is detrimental, such as obesity.

Abstract: Humanized antibodies, or antigen-binding portions thereof, that preferentially bind acylated ghrelin with respect to unacylated ghrelin, are disclosed. These molecules have high affinity and a slow off rate for acylated ghrelin, and neutralize acylated ghrelin activity. These antibodies, or antigen-binding portions thereof, are useful for neutralizing acylated ghrelin activity, e.g., in a subject suffering from a disorder in which ghrelin activity is detrimental, such as obesity.

Abstract: The present invention provides polypeptide Fc region variants and oligonucleotides encoding Fc region variants. Specifically, the present invention provides compositions comprising novel Fc region variants, methods for identifying useful Fc region variants, and methods for employing Fc region variants for treating disease.

Abstract: aPL analogs that (a) bind specifically to B cells to which an aPL epitope binds and are disclosed. Optimized analogs lack T cell epitope(s) are useful as conjugates for treating aPL antibody-mediated diseases. Conjugates comprising aPL analogs and nonimmunogenic valency platform molecules are provides as are novel nonimmunogenic valency platform molecules and linkers. Methods of preparing and identifying said analogs, methods of treatment using said analogs, methods and compositions for preparing conjugates of said analogs and diagnostic immunoassays for aPL antibodies are disclosed.

Abstract: aPL analogs that (a) bind specifically to B cells to which an aPL epitope binds and are disclosed. Optimized analogs lack T cell epitope(s) are useful as conjugates for treating aPL antibody-mediated diseases. Conjugates comprising aPL analogs and nonimmunogenic valency platform molecules are provides as are novel nonimmunogenic valency platform molecules and linkers. Methods of preparing and identifying said analogs, methods of treatment using said analogs, methods and compositions for preparing conjugates of said analogs and diagnostic immunoassays for aPL antibodies are disclosed.

Abstract: aPL analogs that (a) bind specifically to B cells to which an aPL epitope binds and are disclosed. Optimized analogs lack T cell epitope(s) are useful as conjugates for treating aPL antibody-mediated diseases. Methods of preparing and identifying said analogs, methods of treatment using said analogs, methods and compositions for preparing conjugates of said analogs and diagnostic immunoassays for aPL antibodies are disclosed.

Abstract: aPL analogs that (a) bind specifically to B cells to which the aPL epitope binds and (b) lack T cell epitope(s), methods preparing and identifying said analogs and methods of treatment using said analogs are disclosed.